Loading...
•
Jun 30, 2024
Ocugen Q2 2024 Earnings Report
Reported second quarter 2024 financial results and provided a business update.
Key Takeaways
Ocugen reported second quarter 2024 financial results, highlighting progress in their modifier gene therapy platform, including dosing patients in the OCU400 Phase 3 clinical trial and advancing OCU410 into Phase 2. They also received $32.6 million net cash from a public offering, extending their cash runway into Q3 2025.
Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial.
OCU410 preliminary safety and efficacy data expected later this year.
Expanded access program approved for OCU400.
Received $32.6 million net cash from underwritten public offering of common stock.
Forward Guidance
Ocugen expects the cash runway to extend into the third quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...